Kornimate/medical-research-clean huggingface dataset:
assessment of chiropractic treatment: strength and balance

Conditions: Low Back Pain

Summary: this study is a randomized controlled trial designed to compare the effects of 4 weeks of chiropractic care to a waitlist control group on measures of strength, balance, and endurance in military personnel experiencing non-surgical low back pain.

this study will assess three functional outcomes (strength, balance and endurance) and patient-reported outcomes in participants with low back pain (lbp) treated with chiropractic care, providing evidence that may enhance our understanding of the relationship between functional outcomes and chiropractic care. the findings from this study may support the use of chiropractic care for military personnel as an effective, conservative treatment for low back pain that may also help preserve or improve functional outcomes and thus, allow active duty personnel to better perform the physical demands required of them.

Eligibility criteria:
inclusion criteria: 1. age range 18 - ≤ 40, inclusive 2. able to provide written informed consent 3. self-reported acute, subacute or chronic lbp at initial screen and baseline visit 1. pain intensity of ≥ 2 on nrs within the past 24 hours. 4. active duty status exclusion criteria: 1. any chiropractic care within 30 days of informed consent 2. any lbp confirmed or suspected to arise from a visceral source 3. spinal pathology or any other condition(s) contraindicating sm 4. lbp for which specific treatments outside those available within study parameters are indicated 5. any spinal fracture within the past 6 months 6. any spinal surgery within the past 6 months 7. lbp with positive neurologic signs indicating spinal nerve root compression, or lbp with presumptive or confirmed spinal nerve root compression 8. imaging evidence of neuroforaminal or spinal canal stenosis or the clinical presentation of neurogenic claudication 9. chronic pain syndrome diagnosis 10. diagnosis or suspected systemic inflammatory arthropathy of the spine 11. referral needed to evaluate or treat an urgent or emergent condition or to determine the status of a condition that pertains to eligibility 12. unable to safely perform strength, balance, or endurance tests, or the ability to assess health status 13. pregnant or planning to become pregnant within the next 6 weeks 14. knowledge of impending transfer or absence during study period 15. seeking or referred for medical evaluation board / physical evaluation board disability status (to ensure safety while performing study tests and to avoid confounding due to the potential for competing recovery goals) 16. unable or unwilling to comply with study protocols 17. patellar height is \ 25.5 inches

Keywords: chiropractic manipulative therapy low back pain trunk muscle strength balance active military personnel
bibr 277 capsule in patients with essential hypertension

Conditions: Hypertension

Summary: the efficacy and safety of telmisartan capsule in patients with essential hypertension were evaluated in comparison with enalapril maleate in the double blind trial.


Eligibility criteria:
inclusion criteria: * patient is ≥ 25 years of age * patient is either male or female * outpatient. change to inpatient is not allowed during the study period * blood pressure is measured 3 times or more during the 4-week observation period; the last 2 measurements in the sitting position (intervals between measurements must be less than 4 weeks) are stabilized for both of systolic pressure (within +/- 30 mmhg) and diastolic pressure within +/- 15 mmhg) with the mean exceeding 160 mmhg for systolic and 95 mmhg for diastolic pressure exclusion criteria: * patient has severe hypertension (the last 2 measurements in the observation period exceed 120 mmhg in terms of diastolic blood pressure) * patient has secondary or malignant hypertension * patient has a history of severe cardiac failure, unstable angina, or myocardial infarction within previous six months * patient has atrioventricular conduction disturbance, atrial fibrillation or severe arrhythmia * patient has any symptoms of cerebrovascular disorder * patient has serious hepatic dysfunction (either got (glutamic-oxaloacetic transaminase) or gpt (glutamic-pyruvic transaminase) exceeds 100 u) * patient has renal dysfunction (serum creatinin ≥ 2.1 mg/dl) * patient has uncontrolled diabetic (either of the following tests exceeds the specified standards: fasting blood glucose exceeding 151 mg/dl or hba1c exceeding 8%) * patient has a history of drug sensitivity to ace (angiotensin converting enzyme) inhibitors and angiotensin ii receptor antagonists * patient has a history of angioedema due to ace inhibitors * patient has hyperkalemia (k exceeding 5.5 meq/l) * patient has received enalapril just before the start of observation period * patient has received treatment with any other investigational drug(s) within three months of the start of observation period * patients is pregnant, breast-feeding, or possible pregnant, or wants to be pregnant during the study period * patient has any other condition that the investigator or subinvestigator feels would be inappropriate for the study participation
allogeneic stem cell transplant with clofarabine, busulfan and antithymocyte globulin (atg) for adult patients with high-risk acute myeloid leukemia/myelodysplastic syndromes (aml/mds) or acute lymphoblastic leukemia (all)

Conditions: MDS; AML; ALL; BAL

Summary: clofarabine is known to have a stronger anti-tumor effect than fludarabine and has shown its efficacy in treating aggressive acute leukemias. in addition, evidence is that it is well-tolerated with manageable side effects especially in elderly patients. thus, replacing fludarabine with clofarabine in a reduced intensity transplant regimen may provide a regimen with increased anti-tumor activity without adding significant risks of toxicity.the purpose of this study is to evaluate the efficacy and the safety of clofarabine in combination with iv busulfan and atg as the backbone of a reduced intensity conditioning regimen for allogeneic stem cell transplantation for the treatment of patients with high-risk mds/aml or all not eligible to conventional or standard myeloablative allo-sct.


Eligibility criteria:
inclusion criteria: * age 18 to 65 * for patients younger than 50 years, cons-indication for the use of a standard myeloablative conditioning (history of hematopoietic stem cell transplantation autologous or allogeneic, or the presence of co-morbidities or medical history making prohibitive in terms toxicity using chemotherapy and / or high dose radiotherapy as judged by the referring physician) - mds, all or aml at high risk, who the biphenotypic-score \<2 * any primary diagnosis of high-risk mds/aml or all eligible for a treatment by reduced intensity conditioning (ric) allogeneic hematopoietic stem cell transplantation (allo-sct) * suitable donor available (related or matched unrelated) * cardiac: lv ejection fraction ≥ 50% by muga or echocardiogram. * pulmonary: fev1 and fvc ≥ 50% predicted, and dlco (corrected for hemoglobin) ≥ 50% of predicted * adequate renal and hepatic function * performance status: karnofsky ≥ 70% * informed consent signed by patient prior to enrolment exclusion criteria: * age \<18 * age \>65 * known hypersensitivity to clofarabine or excipients- other hematologic malignancies than all, aml and mds * patients with prior standard allogeneic hsct with grade \> 2 agvhd * prior standard allogeneic transplantation if \< 2 months * contra-indication to one of the drug of the ric regimen . * patient with \> 3 treatment lines prior to inclusion * pregnant or lactating females * patient hiv+, hep b+, hep c+- uncontrolled systemic infection * performance status score ecog \> 2- known central nervous system involvement with aml or all- uncontrolled active infection of any kind or bleeding * any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver or other organ system that may place the patient at undue risk to undergo the agents included in the conditioning regimen. * for patients younger than 50 years, possibly indicating a standard myeloablative conditioning

Keywords: mds aml all ric clofarabine allo-hsct high-risk mds/aml
the nor-hand study

Conditions: Osteoarthritis; Pain; Inflammation; Image, Body

Summary: the nor-hand study is a hospital-based observational study including 300 patients with evidence of hand oa by ultrasound and/or clinical examination. the baseline examination (2016-17) consists of functional tests and joint assessment of the hands, medical assessment, pain sensitization tests, ultrasound (hands, acromioclavicular joint, hips, knees and feet), computer tomography (ct) and magnetic resonance imaging (mri) of the dominant hand, conventional radiographs of the hands and feet, fluorescence optical imaging of the hands, collection of blood and urine samples as well as self-reported demographic factors and oa-related questionnaires. two follow-up examinations are planned after 3 (2019-20) and 8 years (2024-25), respectively. cross-sectional analyses will be used to investigate agreements and associations between different relevant measures at the baseline examination, whereas the longitudinal data will be used for evaluation of predictors for clinical outcomes and disease progression.


Eligibility criteria:
inclusion criteria: * age between 40-70 years at screening * proven hand oa by clinical examination and/or ultrasound 1. clinical examination criteria: heberden/bouchards nodes and/or bony enlargement, squaring and/or deformity of the thumb base and no clinical signs of inflammatory arthritis (e.g. soft tissue swelling of two or less metacarpophalangeal (mcp) joints, and no soft tissue swelling of the wrist). 2. ultrasound criteria: osteophytes in the interphalangeal joints and/or the thumb base, and no signs of inflammatory arthritis (e.g. synovitis with power doppler activity in two or less mcp joints and no synovitis with power doppler activity in the wrist). * capable of understanding and signing an informed consent form * provided a written informed consent to participate in the study exclusion criteria: * diagnosis of inflammatory arthritic disease, e.g. seropositive or seronegative rheumatoid arthritis, psoriatic arthritis, reactive arthritis, spondyloarthritis or arthritis related to connective tissue disorders * diagnosis of psoriasis * erythrocyte sedimentation rate (esr) \> 40 mm/hour and/or c-reactive protein (crp) \>20 mg/l, without a known ongoing infection * anti cyclic citrullinated protein (anti-ccp) and/or rheumatoid factor positivity * ferritin \>200 microgram/l for women and \>300 microgram/l for men and s-iron/s-total iron binding capacity (tibc) above 50% * major co-morbidities (e.g. severe malignancies, severe diabetes mellitus, severe infections, uncontrollable hypertension, severe cardiovascular disease or severe respiratory disease) * mental or psychiatric disorders, alcohol or drug abuse, language difficulties or other factors that make compliance to the study protocol difficult.
effect of bradykinin receptor antagonism on ace inhibitor-associated angioedema

Conditions: ACE Inhibitor-associated Angioedema

Summary: individuals with heart disease or high blood pressure are often prescribed angiotensin converting enzyme (ace) inhibitors to treat their disease. however, the use of ace inhibitors can be associated with angioedema, a rare but life-threatening condition that causes swelling of the face and other body parts. this study will evaluate the effectiveness of the drug hoe-140 at decreasing symptoms of angioedema in people taking ace inhibitors who develop the condition.

people who take ace inhibitors may develop angioedema, a condition that causes itchy and painful swelling beneath the skin around the eyes, lips, tongue, throat, hands, or feet. in severe cases, the throat may swell, obstructing the airway and leading to breathing difficulty. ace inhibitors prevent the breakdown of a natural chemical in the body called bradykinin. increased levels of bradykinin, which can cause swelling, may contribute to the development of angioedema. blocking bradykinin receptor cells prevents bradykinin from initiating swelling and may lead to a possible decrease in angioedema symptoms. the purpose of this study is to evaluate the effectiveness of hoe-140, a bradykinin receptor blocker, at reducing symptoms in people with ace inhibitor-associated angioedema. this study will enroll people admitted to the emergency room or hospital who have a severe case of ace inhibitor-associated angioedema. participants will be randomly assigned to receive an injection of either hoe-140 or placebo. initially, participants will undergo an electrocardiogram to measure the electrical activity of the heart. then blood pressure measurements, blood collection, a physical exam to determine the extent and duration of swelling, and photographs of the swelling will occur at 2, 4, 8, 16, and 24 hours following the start of treatment. questionnaires will be completed by study staff and participants to assess changes in angioedema symptoms and the extent of swelling. participants will remain in the hospital for 24 to 48 hours, depending on the severity of their symptoms. blood will be collected at a follow-up visit that will occur 7 days after the resolution of angioedema symptoms.

Eligibility criteria:
inclusion criteria: * the subject has ongoing angioedema while taking an ace inhibitor. * the subject is between 18 and 80 years of age. exclusion criteria: * the subject has had angioedema while not taking an ace inhibitor. * the subject's angioedema only involves the bowel. * the subject is known to be pregnant or has a positive urine pregnancy test. * the subject has started on an oral contraceptive within the last 6 months.

Keywords: ace inhibitor angioedema bradykinin swelling
effects of ekko versus conservative treatment for gross motor functions in cerebral palsy patients

Conditions: Cerebral Palsy

Summary: "cerebral palsy (cp) affects gross motor function variably, with the spastic type notably impacting movement, coordination, and balance. research highlights that spastic cp, characterized by muscle stiffness, can severely hinder activities like walking and running. interventions such as gait training and vibrational therapy have shown promise in enhancing muscle function and body movements. a new device, ekko, uses vibrational waves based on neurotransmission cognitive theory to improve gross motor skills in children with cp by applying mechanical vibrations to nerve points.

this study aims to compare the efficacy of ekko therapy with traditional conservative treatments (such as range of motion exercises and balance training) in improving gross motor function in children with cp. conducted over six months with randomized controlled trials, the research seeks to provide evidence-based insights into optimizing rehabilitation strategies for better motor performance and quality of life for cp patients.

Eligibility criteria:
inclusion criteria: * 1. cerebral palsy (cp) * severity: typically applied to those with mild to moderate cp exclusion criteria: * participants without a confirmed diagnosis of cerebral palsy or any other neurological condition * severe cp cases may be excluded
non-invasive determination of cardiac output by electrical velocimetry

Conditions: Cardiac Diseases

Summary: the cardiac output (co) is an important parameter in the diagnosis and therapy of cardiac diseases. the current standard methods for the determination of the co, however, are either invasive (e.g. right heart catheterization) or technically expendable and expensive (magnetic resonance tomography, mrt). therefore the aim of the study at hand was to evaluate the electrical velocimetry technique as a new method for determining the co and to compare this new technique with the inert gas rebreathing method and with the magnetic resonance tomography


Eligibility criteria:
inclusion criteria: * indication for cmr * ability of following instructions for electrical velocimetry test, rebreathing test and spirometry
impact of consumption of orange-fleshed sweet potatoes on the vitamin a status of bangladeshi women of reproductive age

Conditions: Vitamin A Deficiency

Summary: the primary purpose of this study is to determine whether daily consumption of orange-fleshed sweet potatoes increases the vitamin a status of bangladeshi women of reproductive age. secondary purposes of the study are to determine whether consumption of orange-fleshed sweet potatoes has an effect on the intestinal absorption of dietary iron or dietary zinc in bangladeshi women of reproductive age.

biofortification of plant source foods is a promising strategy for increasing dietary vitamin a intake and vitamin a status in populations at risk of deficiency. the primary purposes of this study are: 1. to assess the efficacy of daily consumption of boiled or fried orange-fleshed sweet potatoes (ofsp) for increasing the vitamin a status of non-pregnant, non-lactating bangladeshi women, and 2. to estimate the relative vitamin a equivalency of beta-carotene from the two different preparations of ofsp (boiled or fried). secondary purposes are to assess the effect of daily consumption of ofsp on intestinal absorption of iron and zinc. specifically, 120 non-pregnant, non-lactating women at risk of vitamin a deficiency will be randomly assigned to one of the following 4 treatment groups to receive, 600 micrograms rae/d, 6 d/wk, for 60 days as either: 1. boiled ofsp 2. fried ofsp 3. retinyl palmitate, or 0 micrograms rae/d as white-fleshed sweet potato (wfsp) the paired stable isotope dilution technique will be used to estimate total body vitamin a pool size before and after 60-days of supplementation. the efficacy of consumption of ofsp will be assessed by comparing the mean change in vitamin a pool size in the ofsp groups to the mean change in vitamin a pool size in the negative control group (wfsp group). relative vitamin a equivalency factors will be estimated by comparing the mean change in vitamin a pool size in the ofsp groups with the mean change in vitamin a pool size in the retinyl palmitate group. intestinal iron absorption and iron status will be assessed before and after the 60-day supplementation period in a subset of women (n=50); and intestinal zinc absorption and zinc status will be assessed after the 60-day supplementation period (n=50). intestinal absorption of iron and zinc will be compared by treatment group to determine whether consumption of ofsp has any effect on iron or zinc absorption in these women.

Eligibility criteria:
inclusion criteria: * serum retinol concentration \< 1.12 umol/l * serum c-reactive protein concentration \< 10 mg/l exclusion criteria: * pregnant * lactating * diarrhea within past week * severe anemia (\< 9g hb/dl) * symptoms of nightblindness * clinical symptoms of xerophthalmia * chronic disease

Keywords: stable isotopes vitamin a beta-carotene orange-fleshed sweet potatoes iron zinc absorption bioavailability vitamin a equivalency bangladesh women
intracutaneous sterile water and diclofenac sodium injections in renal colic

Conditions: Renal Colic

Summary: renal colic is a serious and excruciatingly painful condition that frequently presents itself in the emergency department. in this trial, patients with renal colic who have received intramuscular diclofenac sodium injection or intracutaneous sterile water injection will have their visual analogue scale (vas) measured and compared.

renal colic affects over 12% of the global population at some point in their lives, and recurrence rates are 50%. renal colic affects approximately 1.2 million people annually and is the reason for 1% of emergency department visits and hospital stays. urinary tract obstruction caused by calculi is the most common cause of renal colic occurrence. the sudden onset of colicky pain that begins in the flank and radiates to the groin is the classic clinical feature of a ureteric colic. most people agree that this pain is the worst that humans have ever felt. renal colic pain can be effectively managed with a variety of pharmacologic treatments, including nonsteroidal anti-inflammatory drugs (nsaids), opioid analgesics, antispasmodics, and antidiuretic hormones. however, the best analgesic regimen has not yet been identified. in patients with renal colic, intravenous (iv) injections of analgesics-either opioids or nsaids-remain standard clinical procedures for managing pain. while there have been reports of success with iv administration of these medications, side effects and availability are typically problematic, particularly in private clinics or with opioid abuse. furthermore, because nsaids may reduce renal blood flow and obstruct the kidney's autoregulatory response to obstruction, preexisting renal disease may exacerbate renal failure. the majority of doctors are also uncomfortable using these medications because of their side effects, which include hypotension, respiratory depression, dizziness, nausea, vomiting, narcotic dependence, sedation, and lightheadedness. therefore, it would appear that using alternate treatments to manage renal colic pain is inevitable. in this trial, the investigators will compare the visual analogue scale (vas) in patients with renal colic after being managed with intracutaneous sterile water injection and intramuscular diclofenac sodium injection.

Eligibility criteria:
inclusion criteria: * patients between the ages of 18 and 65. * patients with renal colic at the emergency department of the 30 june center for urology and nephrology, ismailia, egypt. exclusion criteria: * cardiovascular diseases. * renal, and hepatic dysfunction. * hypersensitivity to any of the used drugs. * addiction or chronic use of opioids.